Bharat Biotech today announced that it has commenced Phase I clinical evaluation of HN-VAC, its cell culture based H1N1 vaccine candidate. Bharat Biotech received the nod from Drugs Controller General of India (DCGI) to conduct the Phase I clinical trials. This vaccine under development will boost immunity against the new H1N1 influenza strains, and help protect public health as the pandemic evolves... 
More...
More...